Mohammad Ansari, MD
Pulmonary Disease · Greenville, SCNPI 1821047044
Payments from drug & device makers
Across 92 payments — averaging $30.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$631
- Edwards Lifesciences$262
- GSK$193
- Genentech USA, Inc.$182
- Boehringer Ingelheim$172
- Inari Medical, Inc.$170
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,61594%
- Education$1546%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 24 | $631 |
| Edwards Lifesciences | 2 | $262 |
| GSK | 12 | $193 |
| Genentech USA, Inc. | 4 | $182 |
| Boehringer Ingelheim | 5 | $172 |
| Inari Medical, Inc. | 1 | $170 |
| Axsome Therapeutics, Inc. | 2 | $138 |
| Regeneron Healthcare Solutions, Inc. | 2 | $133 |
| ZOLL Respicardia, Inc. | 1 | $122 |
| Merck | 6 | $102 |
| AstraZeneca | 5 | $88 |
| Jazz Pharmaceuticals Inc. | 3 | $69 |
| Nuwellis, Inc. | 2 | $60 |
| Organogenesis Inc. | 1 | $40 |
| Sunovion Pharmaceuticals Inc. | 3 | $37 |
| Verona Pharma, Inc. | 2 | $33 |
| United Therapeutics Corporation | 1 | $30 |
| Grifols USA, LLC | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Harmony Biosciences LLC | 1 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Philips North America LLC | 1 | $23 |
| Treace Medical Concepts, Inc. | 1 | $22 |
| Amgen | 1 | $21 |
| Novartis | 1 | $20 |
| Advanced Respiratory, Inc | 1 | $19 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $15 |
| Sanofi | 1 | $15 |
| Circassia Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Arikayce$258
- FlowTriever$170
- ClotTriever$170
- SUNOSI$123
- remede System$122
- DUPIXENT$114
How this compares
$2,769 in reported general payments places this provider in the 45th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 23 | $395,061 |
| XyremSodium Oxybate | 13 | $194,977 |
| Dupixent PenDupilumab | 13 | $47,502 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $23,835 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $23,386 |
| Spiriva RespimatTiotropium Bromide | 22 | $13,202 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $10,658 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $8,624 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 135 | $5,656 |
| SymbicortBudesonide/Formoterol Fumarate | 24 | $5,471 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $4,378 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $3,534 |
| Fluticasone Propionate | 161 | $2,067 |
| Montelukast Sodium | 282 | $2,061 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $193 | $66,503117 claims |
| Boehringer IngelheimSpiriva Respimat | $172 | $13,20222 claims |
| AstraZenecaSymbicort | $88 | $5,47124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Greenville
- Sean CallahanGreenville$501K
- Adam SchertzGreenville$54K
- Daniel Lo VerdeGreenville$14K
- Michael KasterGreenville$13K
- Charles FogartySpartanburg$18.7M
- Gregory FeldmanColumbia$15.1M
- Farhan SiddiquiSpartanburg$8.6M
- Joseph BosciaSpartanburg$7.9M
- Charles ThompsonAnderson$7.7M
- David ErbSpartanburg$7.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.